Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR
$2.19
$-1.21
(-35.60%)
As on 23-Sep-2026 12:28EDT
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$0
-
EPS
$-0
-
Face value
--
-
Shares outstanding
2,142,547
10 Years Aggregate
CFO
$-86.58 Mln
EBITDA
$-84.58 Mln
Net Profit
$-87.66 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
| -45.3 | -- | -- | -82.7 | -64.9 | -63.4 | -56.0 |
|
BSE Sensex
| -11.6 | -3.5 | -2.9 | -8.9 | 4.3 | 4.9 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
| -87.7 | -26.0 | -64.1 | -52.7 | -27.5 | -46.1 | -82.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
|
2.2 | 4.8 | 0.4 | -9.9 | -2,456.8 | -179.7 | -- | 1.0 |
| 12.4 | 776.2 | 0.0 | -175.9 | -- | -106.8 | -- | 4.9 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 14.2 | 2,376.0 | 549.1 | 17.9 | -6.3 | 1.4 | 136.7 | 1.9 | |
| 14.9 | 680.4 | 0.0 | -29.0 | 0.0 | -20.4 | -- | 2.3 | |
| 15.3 | 1,964.7 | 120.8 | -57.8 | -42.4 | -9.9 | -- | 3.4 | |
| 11.1 | 746.7 | 366.5 | 9.3 | 8.3 | 3.4 | 75.4 | 2.8 | |
| 11.3 | 758.3 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 20.6 | |
| 6.5 | 622.0 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.7 | |
| 26.5 | 2,885.2 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 4.7 |
Shareholding Pattern
View DetailsAbout Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead... drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. Read more
-
Founder, Chief Scientific Officer & Executive Chairperson
Dr. Pnina Fishman Ph.D.
-
Founder, Chief Scientific Officer & Executive Chairperson
Dr. Pnina Fishman Ph.D.
-
Headquarters
Ramat Gan
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
What is the current share price of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR Today?
The share price of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR is $2.19 (NYSE) as of 23-Sep-2026 12:28 EDT. Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR has given a return of -64.89% in the last 3 years.
What is the current PB & PE ratio of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR?
Since, TTM earnings of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.53 |
11.56 |
2024 |
-260.92 |
378.23 |
2023 |
-213.82 |
261.47 |
2022 |
-24.43 |
55.91 |
2021 |
-34.03 |
29.80 |
What is the 52 Week High and Low of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR?
The 52-week high and low of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR are Rs 88.00 and Rs 2.18 as of 23-Sep-2026.
What is the market cap of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR?
Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR has a market capitalisation of $ 5 Mln as on 18-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR?
Before investing in Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.